Search Results
You searched for "Merck" ( 316 results )
-
Hyundai Bioscience COVID-19 treatment candidate shows efficacy with dexamethasone
South Korean biotechnology firm Hyundai Bioscience Co. said Tuesday that the combination of its oral antiviral candidate and dexamethasone showed high efficacy in treating COVID-19 during animal testings. The company is currently re-purposing niclosamide-based CP-COV03 as a potential treatment for the COVID-19 virus. The investigative drug's indication also includes influenza. Citing the result of the latest animal testing, Hyundai Bioscience said use of both CP-COV03 and dexamethasone resulte
Industry Dec. 7, 2021
-
Korea bans foreign arrivals from eight African countries over omicron
South Korea is implementing tougher entry rules for arrivals from eight African countries in response to omicron, a new and potentially more contagious variant of COVID-19 first identified in South Africa and Botswana, starting Saturday at midnight. The Korea Disease Control and Prevention Agency called an emergency meeting Saturday evening with 13 ministries and announced that all foreigners who have been in the newly listed African countries will be refused entry to Korea. The travel restr
Social Affairs Nov. 28, 2021
-
Korea reviewing emergency approval for Merck’s COVID-19 pills
The Ministry of Food and Drug Safety is looking at data on the COVID-19 antiviral pill from Merck for emergency use approval, the result of which, he said, is anticipated to be out sometime next month, Kim Gang-lip, who heads the ministry said Wednesday. Merck is one of two companies that Korea has entered an advance purchase deal with for their oral medicines, the other being Pfizer. Pfizer, as of Wednesday, has yet to submit an emergency approval application. Kim said the ministry was aimi
Social Affairs Nov. 17, 2021
-
[Mihir Sharma] COVAX needed for climate
When he stunned the Glasgow climate conference by committing India to achieving net-zero emissions by 2070, Indian Prime Minister Narendra Modi issued a crucial caveat. Without the “transfer of climate finance and low-cost climate technologies,” he said, developing nations such as India would never be able to achieve their ambitious targets. That’s not an idle worry. If we have learned anything during the COVID-19 pandemic, it’s that the developing world cannot count on
Viewpoints Nov. 17, 2021
-
[Michael R. Strain] Big business can’t rely on Republicans anymore
The marriage between big business and the Republican Party has long been one of the strongest in American politics. But that relationship is on the rocks, and the rift is growing wider and wider. The conflict puts business leaders in the agonizing position of being caught between newly hostile Republicans and traditionally antagonistic Democrats. The correct response is not to commit to either party, but to find allies in both. Importantly, executives need to engage in a campaign of persuasion
Viewpoints Nov. 16, 2021
-
Korea to get COVID-19 pills ‘no later than February’: vice health minister
South Korea plans to bring oral antivirals against COVID-19 to the country “no later than February,” Vice Minister of Health and Welfare Yoo Geun-heag told reporters Tuesday, in addition to the 90 million doses of vaccines that will be purchased for the third year of the pandemic. While refraining from calling oral antivirals a pandemic “game changer,” he said the government was working to make them available here possibly by January, a month earlier than previously p
Social Affairs Nov. 9, 2021
-
Number of critically ill COVID patients rises after rules relaxed
The number of seriously ill COVID-19 patients has risen steadily since Nov. 1, when rules were eased for public gatherings and working hours at public facilities such as restaurants and cafes. The change came into effect as part of a step-by-step transition by health authorities to remove all restrictions by February. This weekend some 3,000 South Koreans attended rallies in downtown Seoul, while many others took advantage of the increased freedom in public places. But Korea is seeing an incr
Social Affairs Nov. 7, 2021
-
Local COVID-19 treatment developers at a crossroads
South Korean drugmakers are at a crossroads on whether or not to continue developing COVID-19 treatments, as vaccination rates rise across the world and the first drug from global pharmaceutical Merck is set to debut soon. Some have already given up. Merck’s recent decision to give away patents related to molnupiravir, which would become the world’s first COVID-19 pill, for developing countries to produce generic drugs, could prompt latecomers to drop out of the race, industry sou
Technology Oct. 31, 2021
-
Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract Development Manufacturing Organization (CDMO) experience - Reinforces company's ambition to accelerate growth in "Big Three" businesses, including its Process Solutions' CDMO servi
PR Newswire Oct. 28, 2021
-
Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when dermal follicle papilla cells, which draw nutrients from capillaries and allow hair to grow, do not function properly. Treatment that proliferates these cells and transplants them into hair
PR Newswire Oct. 28, 2021
-
Merck’s M Lab Collaboration Center marks 5th year anniversary
Merck, the German science and technology group, on Thursday celebrated the fifth anniversary of its M Lab Collaboration Center in Songdo, Incheon. The M Lab Collaboration Center is a research facility established to support local pharmaceutical and bio industry experts with hands-on and virtual training. “Since its establishment in 2016, our Songdo M Lab Collaboration Center has supported more than 100 biopharmaceutical and biotech customers including Samsung Biologics, Celltrion and SK
Technology Oct. 21, 2021
-
Cambridge Quantum Releases World's First Quantum Natural Language Processing Toolkit and Library
Converting sentences into quantum circuits, 'lambeq' accelerates the development of practical QNLP applications as quantum computing systems scale CAMBRIDGE, England, Oct. 13, 2021 /PRNewswire/ -- Cambridge Quantum ("CQ") today announced the release of the world's first toolkit and library for Quantum Natural Language Processing (QNLP). The toolkit is called lambeq, named after the late mathematician and linguist Joachim Lambek. lambeq is the world's first software toolki
PR Newswire Oct. 13, 2021
-
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors Investment serves customers in addressing larger patient populations with new curative treatments Enables suspension production of viral vectors up to 1,000-liter scale Project adds to company's ambition to accelerate growth through investments in "Big 3" businesses, which includes plans to expand Process Solutions' contract manufacturing a
PR Newswire Oct. 12, 2021
-
German tech firm Merck to invest $693m in S. Korea by 2025
Germany-based technology firm Merck Group said Friday it plans to invest around $693 million in South Korea through 2025 in the electronics sector, including semiconductor solutions. The investment by Merck is expected to lend hands to South Korea's so-called K-semiconductor blueprint, and help the country secure a stable supply chain of related materials, according to the Ministry of Trade, Industry and Energy. The company entered the South Korean market in 1989 and currently operates 11 res
Industry Oct. 8, 2021
-
Koreans dump Tesla shares, turn to US health care sector in Q3
South Korea-domiciled investors went on to sell Tesla stocks during the third quarter of this year, and instead turned to health care stocks in the United States, data showed Wednesday. This indicates that Korean investors’ enthusiasm over the growth potential of the Palo Alto, California-based electric vehicle giant since early 2020 has started to wane. Instead, they were seen betting on normalization hopes amid a fight against the COVID-19 pandemic. From July to September, Korean inv
Market Oct. 6, 2021
-
[팟캐스트] (424) 먹는 코로나 치료제 등장으로 위드코로나 기대감 상승 / 부실수사 논란에 공군본부 직할 ‘수사단’ 창설
진행자: 고준태, Brolley Genster 1. S. Korea’s hope for normalization boosted with positive trial results from Merck 요약: 미국 글로벌 제약사 머크가 개발한 코로나19 경구용 치료제 후보물질 ‘몰누파라비르’의 긍정적인 연구결과에 ‘위드 코로나’로 갈 수 있는 분기점이 마련될 전망이다. 정부는 경구용 치료제 도입을 위해 올해 추경을 통해 1만8000명분의 예산을 확보한 바 있다. [1] South Korea’s plan to step into a phased recovery back to normal life in November is gaining support with positive clinical test results of an experimental COVID-19 oral medication overseas.
Podcast Oct. 6, 2021
-
Bali to reopen direct flights from China, Japan, South Korea
Indonesia’s tourist spot Bali will start allowing direct arrivals from China, Japan and South Korea as a receding Covid-19 outbreak lets the country ease restrictions further. Foreign visitors from New Zealand, Qatar and United Arab Emirates can also enter the country through the island’s Ngurah Rai International Airport starting from Oct. 14, said Luhut Panjaitan, coordinating minister for investment and maritime affairs who’s overseeing the pandemic response. Only Jakarta an
Social Affairs Oct. 4, 2021
-
S. Korea’s hope for normalization boosted with positive trial results from Merck
South Korea’s plan to step into a phased recovery back to normal life in November is gaining support with positive clinical test results of an experimental COVID-19 oral medication overseas. Leading global drugmaker Merck & Co announced Friday that its experimental antiviral pill dubbed molnupiravir was shown to halve the chances of hospitalization or death for those infected with COVID-19. Merck and its partner Ridgeback Biotherapeutics reported that 7.3 percent of patients who rece
Social Affairs Oct. 2, 2021
-
S. Korean biotech firm Genome & Company to acquire US-based CDMO
South Korean biotech firm Genome & Company will acquire a 60 percent stake in US-based contract development and manufacturing organization List Biological Laboratories for $27 million, the company announced Wednesday. With the acquisition, Genome & Company, which specializes in immuno-oncology, seeks to secure materials needed for future clinical trials of microbiome-based therapies, CEO Bae Ji-soo told an online press conference. Founded in 1978, List Labs is a CDMO firm that owns m
Technology Sept. 8, 2021
-
Samsung Bioepis sees 30% jump in biosimilar sales in H1
South Korean drugmaker Samsung Bioepis said Friday that global sales of five major biosimilar products increased 30 percent on-year in the first half of this year. Sales of the five biosimilar products during the first half reached $166 million, from $128 million from the same period a year earlier, according to an earnings report of its global pharmaceutical partner Organon International, a spinoff of US-based Merck. The five products are etanercept, infliximab, adalimumab, trastuzumab and
Technology Aug. 13, 2021
Most Popular
-
1
Tensions heighten ahead of first president-opposition chief meeting
-
2
Seoul to provide housing subsidy to married couples with newborns
-
3
[KH Explains] No more 'Michael' at Kakao Games
-
4
Rapper jailed after public street fight with another rapper
-
5
Woman gets suspended term for injuring boyfriend with knife
-
6
Samsung chief bolsters ties with Germany’s Zeiss
-
7
NewJeans pops out ‘Bubble Gum’ video amid troubles at agency
-
8
Nominee for chief of anti-corruption body pledges 'independence, effectiveness'
-
9
Med schools expect 1,500+ new admission slots next year
-
10
KT launches new mobile plans for foreign residents